Fudan University Cancer Center Trials

Fudan University Cancer Center	Welcome, Profile Billing Logout

87 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Shao, Zhimin

NCT05871437: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Recruiting

379

RoW

Huaier granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Early-stage Breast Cancer

10/24

08/25

NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Not yet recruiting

384

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Breast Cancer Stage IV

10/25

10/27

NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting

1072

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast

12/27

07/28

PANSY, NCT04193059: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Recruiting

1560

RoW

Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Trastuzumab, Pertuzumab, Docetaxel

Fudan University

Breast Cancer

07/21

07/24

NCT03980054: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Active, not recruiting

1192

RoW

Pyrotinib, Placebo

Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

07/22

07/24

NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed

517

RoW

Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery

Qilu Pharmaceutical Co., Ltd.

Breast Cancer

08/22

10/23

CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Recruiting

2172

RoW

Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection

Fudan University

Breast Cancer

11/24

11/25

NCT04613674: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Completed

441

RoW

Camrelizumab Plus Chemotherapy, placebo+chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Triple Negative Breast Cancer

09/23

03/24

NCT06447623: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Recruiting

184

RoW

Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant

Fudan University

Advanced Breast Cancer, HR+/HER2- Breast Cancer

02/27

02/29

SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting

524

RoW

SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Triple Negative Breast Cancer

07/26

Rainbow, NCT06341621: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Recruiting

1900

RoW

3-year abemaciclib without chemo, treatment of physician's choice

Fudan University

Breast Cancer

02/27

01/29

NCT04403529: Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Recruiting

200

RoW

Traditional Chinese Medicine Formulation, "prescription for breast cancer" Traditional Chinese Medicine formulation, Placebo Formulation, Placebo granules contains 5% "prescription for breast cancer" Traditional Chinese Medicine formulation and 95% filler

Fudan University

Triple Negative Breast Cancer

05/24

CITRINE, NCT04296175: Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer

Active, not recruiting

808

RoW

Epirubicin, CTX, Paclitaxel, ddEpirubicin, ddCTX, Paclitaxel(with carbo), Carboplatin

Fudan University

Triple-negative Breast Cancer

03/25

03/27

GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting

200

RoW

T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection

Changchun GeneScience Pharmaceutical Co., Ltd.

Breast Cancer Subjects

11/25

03/26

NCT06846437: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting

228

RoW

JSKN003, Trastuzumab emtansine (T-DM1)

Shanghai JMT-Bio Inc.

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

10/26

12/28

ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

NCT05673629: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Recruiting

552

RoW

Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC

Beijing Biostar Pharmaceuticals Co., Ltd.

Breast Cancer

06/25

12/25

BCTOP-T-M03, NCT05954442: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting

203

RoW

Everolimus, Afinitor, Investigator's Choice of Chemotherapy, ICC

Fudan University

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation

08/25

08/26

DYNASTY-Breast02, NCT06018337: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Recruiting

532

Europe, Canada, US, RoW

DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel

DualityBio Inc., BioNTech SE

Metastatic Breast Cancer

05/26

07/28

NCT05999149: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Recruiting

424

RoW

Camrelizumab Plus Chemotherapy and Famitinib, camrelizumab+chemotherapy+Famitinib, Camrelizumab Plus Chemotherapy

Fudan University

TNBC - Triple-Negative Breast Cancer

08/25

08/27

NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Recruiting

844

RoW

Tamoxifen, Tamoxifen citrate, Toremifene, fareston

Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University

Breast Cancer Female

12/25

NCT05883852: EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Recruiting

1406

RoW

Docetaxel, carboplatin, Trastuzumab, Pertuzumab, Epirubicin, cyclophosphamide

Fudan University

HER2 Positive Early Breast Cancer

07/31

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT06891833: A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Not yet recruiting

2/3

120

RoW

BL-M07D1, Pertuzumab, Taxane

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

HER2-positive Breast Cancer

12/28

FUTURE-C-PLUS, NCT04129996: A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer

Active, not recruiting

RoW

camrelizumab in combination with nab-paclitaxel and famitinib

Fudan University

Triple-Negative Breast Cancer

09/22

BGB-900-2001-IIT, NCT04734262: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active, not recruiting

RoW

Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Nab-paclitaxel, Nanoparticle albumin-bound paclitaxel

Fudan University

Metastatic Breast Cancer

06/24

Renaissance, NCT05076682: Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

RoW

Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz

Fudan University

Triple-negative Breast Cancer

12/22

03/23

MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting

319

RoW

SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi

Fudan University

Breast Cancer, Metastatic Cancer

05/23

04/25

NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting

120

RoW

Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks）

RemeGen Co., Ltd.

Breast Cancer

12/25

12/26

NCT05670925: A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Recruiting

RoW

Camrelizumab plus Famitinib with/without nab-Palitaxel

Fudan University

Triple-Negative Breast Cancer

09/23

NeoTPPF, NCT05076695: Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Recruiting

RoW

Palbociclib, trastuzumab, pyrotinib, fulvestrant

Fudan University

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer

10/23

10/24

FUTURE-SUPER, NCT04395989: An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Active, not recruiting

139

RoW

A1: Pyrotinib with nab-paclitaxel, SHR1258, A2: nab-paclitaxel, B1: everolimus with nab-paclitaxel, B2: nab-paclitaxel, C1: PD-1 with nab-paclitaxel and famitinib, Camrelizumab, SHR1210, C2: nab-paclitaxel, D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), D2: nab-paclitaxel, with maintenance of capecitabine, E1: everolimus with nab-paclitaxel, E2: nab-paclitaxel

Fudan University

TNBC - Triple-Negative Breast Cancer

05/23

12/24

TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Recruiting

104

RoW

6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

01/25

02/26

NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Recruiting

RoW

Cryoablation Combined with Tirelizumab and Bevacizumab

Fudan University

Metastatic Breast Cancer in the Liver

04/24

QUEEN-Neo, NCT06404463: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting

QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin, Cyclophosphamide, Epirubicin

Fudan University

Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer

11/25

11/30

NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Recruiting

RoW

Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Fudan University

Triple-negative Breast Cancer

12/24

01/25

NCT06516926: SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Not yet recruiting

240

RoW

SHR-4602

Jiangsu HengRui Medicine Co., Ltd.

HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

11/25

12/26

abemaSNF1/3, NCT06561022: Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

Not yet recruiting

260

RoW

Fluzoparib, Everolimus, Fulvestrant, Abemaciclib

Fudan University

Breast Cancer

12/25

06/26

NCT05577923: Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Not yet recruiting

126

RoW

Trastuzumab, pyrotinib, Dalpiciclib, fulvestrant

Fudan University

Metastatic Breast Cancer

09/24

03/26

FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting

716

RoW

Dalpiciclib, SHR-6390, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-1210, SHR-A1921, Pertuzumab, Trastuzumab, Goserelin, Letrozole, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Fluzoparib, SHR-3162, Apatinib, Famitinib

Fudan University

Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer

12/24

09/25

NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting

120

RoW

SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102

Fudan University

Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer

09/26

09/27

NCT05749588: FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Recruiting

120

RoW

A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, SHR-1210, B1: TROP2 ADC, B2: TROP2 ADC with Camrelizumab, C1: SHR-A1811, C2: SHR-A1811 with BP102, D1: TROP2 ADC, D2: TROP2 ADC with BP102, E1: SHR-A1811, F1: TROP2 ADC, G1: SHR-A1811, H1: TROP2 ADC

Fudan University

Triple-negative Breast Cancer

BCTOP-L-M01, NCT05949541: Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Recruiting

265

RoW

Everolimus 10 mg, Afinitor, CDK4/6 Inhibitor SHR6390, Dalpiciclib, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors, Endocrine therapy

Fudan University

Breast Cancer, Advanced Breast Cancer

07/26

01/28

FINEST, NCT04215003: A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Recruiting

1/2

RoW

A, B, CL4

Fudan University

Breast Cancer

12/24

FUTURE, NCT03805399: FUSCC Refractory TNBC Umbrella

Recruiting

1/2

140

RoW

Pyrotinib with Capecitabine, SHR1258, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), SHR3680 SHR6390, anti PD-1 with nab-paclitaxel, SHR1210, PARP inhibitor included therapy, SHR3162, BLIS with anti-VEGFR included therapy, YN968D1, MES with anti-VEGFR included therapy, mTOR inhibitor with nab-paclitaxel, everolimus

Fudan University

Triple-negative Breast Cancer

12/22

NCT04413409: A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)

Recruiting

N/A

172

RoW

Metastasectomy for the metastatic sites

Fudan University

Breast Cancer

03/23

03/25

MTT-BC-001, NCT06635096: The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer

Not yet recruiting

N/A

RoW

Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)

Fudan University

Breast Cancer Female

03/26

10/26

NCT06636591: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Recruiting

N/A

RoW

Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin, Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin

Fudan University

Breast Cancer Female, HER2-negative Breast Cancer

02/25

10/26

ALPHABET-001, NCT06718010: The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer

Recruiting

N/A

120

RoW

No intervention (observational study)

Fudan University

Breast Cancer, Age

03/26

NCT04334785: Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer

Recruiting

N/A

186

RoW

cryo-ablation

Fudan University

Breast Cancer

05/25

NeoaPET, NCT05914402: Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET

Recruiting

N/A

100

RoW

axillary surgery de-escalation after NAT

Fudan University

Breast Cancer

12/25

Yang, Jin Mo

RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting

366

RoW

RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda

RemeGen Co., Ltd.

Breast Cancer

06/24

12/24

NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

Completed

765

RoW

TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group

Vigonvita Life Sciences

Erectile Dysfunction

02/23

HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

	Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
	Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer

Active, not recruiting

466

Europe, Canada, Japan, US, RoW

tucatinib, ONT-380, placebo, T-DM1, Kadcyla

Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc., Seattle Genetics, Inc., Seagen Inc

HER2-positive Breast Cancer

06/23

10/27

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Recruiting

120

RoW

Trastuzumab, herceptin；Inetetamab, Pertuzumab, Perjeta, Nab paclitaxel, Abraxane, Pyrotinib, SHR-1258, Capecitabine, T-DM1, Trastuzumab Emtansine, Everolimus, RAD001, CDK4/6 inhibitor, Palbociclib；, AI, Letrozole, Anti-PD-1 monoclonal antibody, Sintilimab

First Affiliated Hospital Xi'an Jiaotong University

HER2+ Breast Cancer

02/24

NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Recruiting

472

RoW

TPN171H, Simmerafil

Vigonvita Life Sciences

Erectile Dysfunction

04/25

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting

400

RoW

JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Breast Cancer

04/25

03/29

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Recruiting

766

RoW

Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist

Fudan University

Breast Cancer

05/28

05/31

BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients

Recruiting

548

RoW

Antivascular therapy, Chemotherapy

Fudan University

Breast Cancer, Triple Negative Breast Cancer

05/29

05/31

OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting

2/3

549

Europe, RoW

Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®

Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.

Recurrent or Metastatic Breast Cancer

02/24

12/25

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

254

RoW

SPH4336 Tablets, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

12/25

CATPCC-01, NCT06511726: Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting

RoW

Cadonilimab, AK-104

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Cervical Cancer

10/25

10/27

NCT05429294: Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Recruiting

209

RoW

Pyrotinib, Trastuzumab, Albumin paclitaxel

First Affiliated Hospital Xi'an Jiaotong University

HER2-positive Breast Cancer

05/24

10/24

TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

06/26

06/28

TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting

RoW

TQB3616 capsule+Fulvestrant Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

05/26

12/26

NCT05914857: Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Not yet recruiting

120

RoW

Dapagliflozin 10mg Tab, Dapagliflozin Tablets, lifestyle interventions

Yangjin, Peking University Third Hospital

Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance

06/25

12/25

NCT06851442: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Not yet recruiting

1/2

RoW

TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

04/27

TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting

150

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

12/25

12/26

NCT05581888: Visual Performance of Functional Intraocular Lenses in Cataracts

Active, not recruiting

N/A

RoW

trifocal intraocular lens

Eye & ENT Hospital of Fudan University

High Myopia, Cataract

06/21

03/23

NCT04668703: Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema

Not yet recruiting

N/A

Conbercept intravitreal injection

Eye & ENT Hospital of Fudan University

Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic

11/21

01/22

NCT05530473: Combined Capsular Tension Ring and IOL Implantation for Management of Cataracts

Completed

N/A

200

RoW

capsular tension ring, capsular tension ring (ACPi-11; Bausch&Lomb)

Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China

Intraocular Lens Rotation, Capsular Tension Ring

12/22

03/23

NCT05783063: ITBS for Increased Appetite Induced by Antipsychotics

Recruiting

N/A

RoW

Active iTBS, Sham iTBS

Central South University

Schizophrenia

06/26

08/26

NCT05797298: Toric Intraocular Lens (IOL) Implantation for Management of Cataracts

Recruiting

N/A

3000

RoW

Eye & ENT Hospital of Fudan University

Toric Intraocular Lens Stability, Visual Quality

03/24

05/24

NCT06331923: Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes

Recruiting

N/A

10168

RoW

Continuous glucose monitoring (CGM) device

Beijing Tsinghua Chang Gung Hospital, Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital

Comprehensive Complication Index

10/25

12/25

NCT06719739: Functional IOL Implantation in Patients with Epiretinal Membrane

Recruiting

N/A

RoW

Intraocular lens implantation

Eye & ENT Hospital of Fudan University

Cataract, Intraocular Lens Complication, Epiretinal Membrane

09/26

SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting

N/A

1000

RoW

benralizumab

AstraZeneca

Chronic Obstructive Pulmonary Disease

01/26

NCT02182921: Evaluation of Cataract Surgery Outcome

Recruiting

N/A

20000

RoW

Evidence Based Cataract Study Group

Cataract, High Myopia

12/26

12/30

NCT06092164: Visual Outcomes of Functional Intraocular Lenses in Cataracts

Not yet recruiting

N/A

20000

Eye & ENT Hospital of Fudan University

Cataract, Visual Quality

12/29

12/31

COOPERATIONS, NCT05163054: Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China

Not yet recruiting

N/A

500

RoW

Peking University Third Hospital

Type 1 Diabetes

01/32

NCT05682001: The Molecular Pathogenesis Study of Cataract

Recruiting

N/A

150

RoW

Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China

Cataract, Pathogenesis

12/23

12/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Shao, Zhimin

NCT05871437: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Recruiting

379

RoW

Huaier granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Early-stage Breast Cancer

10/24

08/25

NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Not yet recruiting

384

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Breast Cancer Stage IV

10/25

10/27

NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting

1072

RoW

Huaier Granule, Z20000109（NMPA Approval Number）

Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology

Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast

12/27

07/28

PANSY, NCT04193059: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Recruiting

1560

RoW

Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Trastuzumab, Pertuzumab, Docetaxel

Fudan University

Breast Cancer

07/21

07/24

NCT03980054: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Active, not recruiting

1192

RoW

Pyrotinib, Placebo

Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

07/22

07/24

Completed

517

RoW

Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery

Qilu Pharmaceutical Co., Ltd.

Breast Cancer

08/22

10/23

CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Recruiting

2172

RoW

Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection

Fudan University

Breast Cancer

11/24

11/25

NCT04613674: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Completed

441

RoW

Camrelizumab Plus Chemotherapy, placebo+chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Triple Negative Breast Cancer

09/23

03/24

NCT06447623: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Recruiting

184

RoW

Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant

Fudan University

Advanced Breast Cancer, HR+/HER2- Breast Cancer

02/27

02/29

SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting

524

RoW

SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Triple Negative Breast Cancer

07/26

Rainbow, NCT06341621: Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Recruiting

1900

RoW

3-year abemaciclib without chemo, treatment of physician's choice

Fudan University

Breast Cancer

02/27

01/29

NCT04403529: Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Recruiting

200

RoW

Fudan University

Triple Negative Breast Cancer

05/24

CITRINE, NCT04296175: Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer

Active, not recruiting

808

RoW

Epirubicin, CTX, Paclitaxel, ddEpirubicin, ddCTX, Paclitaxel(with carbo), Carboplatin

Fudan University

Triple-negative Breast Cancer

03/25

03/27

GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting

200

RoW

T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection

Changchun GeneScience Pharmaceutical Co., Ltd.

Breast Cancer Subjects

11/25

03/26

NCT06846437: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting

228

RoW

JSKN003, Trastuzumab emtansine (T-DM1)

Shanghai JMT-Bio Inc.

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

10/26

12/28

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

NCT05673629: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Recruiting

552

RoW

Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC

Beijing Biostar Pharmaceuticals Co., Ltd.

Breast Cancer

06/25

12/25

BCTOP-T-M03, NCT05954442: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting

203

RoW

Everolimus, Afinitor, Investigator's Choice of Chemotherapy, ICC

Fudan University

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation

08/25

08/26

DYNASTY-Breast02, NCT06018337: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Recruiting

532

Europe, Canada, US, RoW

DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel

DualityBio Inc., BioNTech SE

Metastatic Breast Cancer

05/26

07/28

NCT05999149: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Recruiting

424

RoW

Camrelizumab Plus Chemotherapy and Famitinib, camrelizumab+chemotherapy+Famitinib, Camrelizumab Plus Chemotherapy

Fudan University

TNBC - Triple-Negative Breast Cancer

08/25

08/27

NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Recruiting

844

RoW

Tamoxifen, Tamoxifen citrate, Toremifene, fareston

Breast Cancer Female

12/25

NCT05883852: EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Recruiting

1406

RoW

Docetaxel, carboplatin, Trastuzumab, Pertuzumab, Epirubicin, cyclophosphamide

Fudan University

HER2 Positive Early Breast Cancer

07/31

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT06891833: A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Not yet recruiting

2/3

120

RoW

BL-M07D1, Pertuzumab, Taxane

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

HER2-positive Breast Cancer

12/28

Active, not recruiting

RoW

camrelizumab in combination with nab-paclitaxel and famitinib

Fudan University

Triple-Negative Breast Cancer

09/22

Active, not recruiting

RoW

Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Nab-paclitaxel, Nanoparticle albumin-bound paclitaxel

Fudan University

Metastatic Breast Cancer

06/24

Renaissance, NCT05076682: Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

RoW

Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz

Fudan University

Triple-negative Breast Cancer

12/22

03/23

MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting

319

RoW

SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi

Fudan University

Breast Cancer, Metastatic Cancer

05/23

04/25

NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting

120

RoW

RemeGen Co., Ltd.

Breast Cancer

12/25

12/26

NCT05670925: A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Recruiting

RoW

Camrelizumab plus Famitinib with/without nab-Palitaxel

Fudan University

Triple-Negative Breast Cancer

09/23

NeoTPPF, NCT05076695: Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Recruiting

RoW

Palbociclib, trastuzumab, pyrotinib, fulvestrant

Fudan University

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer

10/23

10/24

FUTURE-SUPER, NCT04395989: An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Active, not recruiting

139

RoW

Fudan University

TNBC - Triple-Negative Breast Cancer

05/23

12/24

TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Recruiting

104

RoW

6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

01/25

02/26

NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Recruiting

RoW

Cryoablation Combined with Tirelizumab and Bevacizumab

Fudan University

Metastatic Breast Cancer in the Liver

04/24

QUEEN-Neo, NCT06404463: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting

QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin, Cyclophosphamide, Epirubicin

Fudan University

Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer

11/25

11/30

NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Recruiting

RoW

Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Fudan University

Triple-negative Breast Cancer

12/24

01/25

NCT06516926: SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Not yet recruiting

240

RoW

SHR-4602

Jiangsu HengRui Medicine Co., Ltd.

HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

11/25

12/26

abemaSNF1/3, NCT06561022: Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

Not yet recruiting

260

RoW

Fluzoparib, Everolimus, Fulvestrant, Abemaciclib

Fudan University

Breast Cancer

12/25

06/26

NCT05577923: Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Not yet recruiting

126

RoW

Trastuzumab, pyrotinib, Dalpiciclib, fulvestrant

Fudan University

Metastatic Breast Cancer

09/24

03/26

FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting

716

RoW

Fudan University

12/24

09/25

NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting

120

RoW

SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102

Fudan University

Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer

09/26

09/27

NCT05749588: FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Recruiting

120

RoW

Fudan University

Triple-negative Breast Cancer

BCTOP-L-M01, NCT05949541: Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Recruiting

265

RoW

Everolimus 10 mg, Afinitor, CDK4/6 Inhibitor SHR6390, Dalpiciclib, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors, Endocrine therapy

Fudan University

Breast Cancer, Advanced Breast Cancer

07/26

01/28

FINEST, NCT04215003: A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Recruiting

1/2

RoW

A, B, CL4

Fudan University

Breast Cancer

12/24

FUTURE, NCT03805399: FUSCC Refractory TNBC Umbrella

Recruiting

1/2

140

RoW

Fudan University

Triple-negative Breast Cancer

12/22

NCT04413409: A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)

Recruiting

N/A

172

RoW

Metastasectomy for the metastatic sites

Fudan University

Breast Cancer

03/23

03/25

MTT-BC-001, NCT06635096: The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer

Not yet recruiting

N/A

RoW

Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)

Fudan University

Breast Cancer Female

03/26

10/26

NCT06636591: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

Recruiting

N/A

RoW

Fudan University

Breast Cancer Female, HER2-negative Breast Cancer

02/25

10/26

ALPHABET-001, NCT06718010: The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer

Recruiting

N/A

120

RoW

No intervention (observational study)

Fudan University

Breast Cancer, Age

03/26

NCT04334785: Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer

Recruiting

N/A

186

RoW

cryo-ablation

Fudan University

Breast Cancer

05/25

NeoaPET, NCT05914402: Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET

Recruiting

N/A

100

RoW

axillary surgery de-escalation after NAT

Fudan University

Breast Cancer

12/25

Yang, Jin Mo

RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting

366

RoW

RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda

RemeGen Co., Ltd.

Breast Cancer

06/24

12/24

NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

Completed

765

RoW

TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group

Vigonvita Life Sciences

Erectile Dysfunction

02/23

HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

	Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
	Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer

Active, not recruiting

466

Europe, Canada, Japan, US, RoW

tucatinib, ONT-380, placebo, T-DM1, Kadcyla

Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc., Seattle Genetics, Inc., Seagen Inc

HER2-positive Breast Cancer

06/23

10/27

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Recruiting

120

RoW

First Affiliated Hospital Xi'an Jiaotong University

HER2+ Breast Cancer

02/24

NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Recruiting

472

RoW

TPN171H, Simmerafil

Vigonvita Life Sciences

Erectile Dysfunction

04/25

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting

400

RoW

JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Breast Cancer

04/25

03/29

Recruiting

500

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

04/27

04/28

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Recruiting

766

RoW

Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist

Fudan University

Breast Cancer

05/28

05/31

BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients

Recruiting

548

RoW

Antivascular therapy, Chemotherapy

Fudan University

Breast Cancer, Triple Negative Breast Cancer

05/29

05/31

OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting

2/3

549

Europe, RoW

Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®

Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.

Recurrent or Metastatic Breast Cancer

02/24

12/25

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting

2/3

254

RoW

SPH4336 Tablets, SPH4336 Tablets Placebo

Shanghai Pharmaceuticals Holding Co., Ltd

Locally Advanced or Metastatic Breast Cancer

12/25

CATPCC-01, NCT06511726: Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting

RoW

Cadonilimab, AK-104

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Cervical Cancer

10/25

10/27

NCT05429294: Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Recruiting

209

RoW

Pyrotinib, Trastuzumab, Albumin paclitaxel

First Affiliated Hospital Xi'an Jiaotong University

HER2-positive Breast Cancer

05/24

10/24

TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

06/26

06/28

TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting

RoW

TQB3616 capsule+Fulvestrant Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

05/26

12/26

NCT05914857: Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Not yet recruiting

120

RoW

Dapagliflozin 10mg Tab, Dapagliflozin Tablets, lifestyle interventions

Yangjin, Peking University Third Hospital

Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance

06/25

12/25

Not yet recruiting

1/2

RoW

TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

04/27

TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting

150

RoW

TQB2102 for injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Breast Cancer

12/25

12/26

NCT05581888: Visual Performance of Functional Intraocular Lenses in Cataracts

Active, not recruiting

N/A

RoW

trifocal intraocular lens

Eye & ENT Hospital of Fudan University

High Myopia, Cataract

06/21

03/23

NCT04668703: Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema

Not yet recruiting

N/A

Conbercept intravitreal injection

Eye & ENT Hospital of Fudan University

Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic

11/21

01/22

NCT05530473: Combined Capsular Tension Ring and IOL Implantation for Management of Cataracts

Completed

N/A

200

RoW

capsular tension ring, capsular tension ring (ACPi-11; Bausch&Lomb)

Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China

Intraocular Lens Rotation, Capsular Tension Ring

12/22

03/23

NCT05783063: ITBS for Increased Appetite Induced by Antipsychotics

Recruiting

N/A

RoW

Active iTBS, Sham iTBS

Central South University

Schizophrenia

06/26

08/26

NCT05797298: Toric Intraocular Lens (IOL) Implantation for Management of Cataracts

Recruiting

N/A

3000

RoW

Eye & ENT Hospital of Fudan University

Toric Intraocular Lens Stability, Visual Quality

03/24

05/24

NCT06331923: Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes

Recruiting

N/A

10168

RoW

Continuous glucose monitoring (CGM) device

Comprehensive Complication Index

10/25

12/25

NCT06719739: Functional IOL Implantation in Patients with Epiretinal Membrane

Recruiting

N/A

RoW

Intraocular lens implantation

Eye & ENT Hospital of Fudan University

Cataract, Intraocular Lens Complication, Epiretinal Membrane

09/26

SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting

N/A

1000

RoW

benralizumab

AstraZeneca

Chronic Obstructive Pulmonary Disease

01/26

NCT02182921: Evaluation of Cataract Surgery Outcome

Recruiting

N/A

20000

RoW

Evidence Based Cataract Study Group

Cataract, High Myopia

12/26

12/30

NCT06092164: Visual Outcomes of Functional Intraocular Lenses in Cataracts

Not yet recruiting

N/A

20000

Eye & ENT Hospital of Fudan University

Cataract, Visual Quality

12/29

12/31

COOPERATIONS, NCT05163054: Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China

Not yet recruiting

N/A

500

RoW

Peking University Third Hospital

Type 1 Diabetes

01/32

NCT05682001: The Molecular Pathogenesis Study of Cataract

Recruiting

N/A

150

RoW

Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China

Cataract, Pathogenesis

12/23

12/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites